In short
This article discusses a clinical trial investigating the use of [89Zr]BMS-986279, also known as Anti-Fucosyl GM1 PET Tracer, in combination with other drugs for the treatment of extensive-stage small cell lung cancer. The study aims to evaluate the safety, effectiveness, and potential benefits of this new combination therapy compared to standard treatment approaches.
At a glance
- Study Type
- Phase 2 Randomized, Open Label Clinical Trial
- Condition
- Extensive-stage Small Cell Lung Cancer
- Intervention
- [89Zr]BMS-986279 (Anti-Fucosyl GM1 PET Tracer) in combination with other drugs
- Primary Objectives
- Assess safety, tolerability, and progression-free survival
- Secondary Objectives
- Evaluate response rates, survival rates, and immunogenicity
- Key Inclusion Criteria
- ECOG status 0-1, measurable lesions, adequate organ function
- Key Exclusion Criteria
- Pregnancy, certain autoimmune conditions, active pneumonitis
- Primary Endpoints
- Adverse events, progression-free survival
- Secondary Endpoints
- Response rates, survival rates, immunogenicity measures
What is [89ZR]BMS-986279?
[89ZR]BMS-986279 is a medical compound being studied for its potential use in patients with extensive-stage small cell lung cancer. It is classified as an Anti-Fucosyl GM1 PET Tracer, which means it's designed to help doctors see cancer cells more clearly during imaging tests.
Medical Condition
This medication is being investigated for use in extensive-stage small cell lung cancer. Small cell lung cancer is a fast-growing type of lung cancer that often spreads quickly to other parts of the body. The "extensive-stage" means that the cancer has spread beyond one lung or to other parts of the body.
How It Works
[89ZR]BMS-986279 is a PET tracer. PET stands for Positron Emission Tomography, which is an imaging technique used to observe metabolic processes in the body. The tracer is designed to attach to specific cancer cells, making them more visible during a PET scan. This can help doctors better identify the location and extent of cancer in a patient's body.
Administration
According to the clinical trial information, [89ZR]BMS-986279 is administered through intravenous use. This means it's given directly into a vein. The dose is measured in MBq (megabecquerels), which is a unit used to measure radioactivity.
Clinical Trial Information
The medication is currently being studied in a clinical trial. Here are some key points about the trial:
- It's a Phase 2 trial, which means it's testing the effectiveness and safety of the medication in a larger group of patients.
- The trial is comparing different treatment combinations for patients with extensive-stage small cell lung cancer.
- The main goal is to assess how safe and effective the treatments are, and how long patients live without their cancer getting worse.
It's important to note that [89ZR]BMS-986279 is being used alongside other cancer treatments in this trial, including chemotherapy drugs (carboplatin and etoposide) and an immunotherapy drug (nivolumab).
Potential Benefits
While the full benefits of [89ZR]BMS-986279 are still being studied, it has the potential to:
- Improve the accuracy of cancer imaging, helping doctors better understand the extent of a patient's cancer
- Aid in monitoring how well treatment is working
- Potentially lead to more personalized treatment plans for patients with extensive-stage small cell lung cancer
Safety Considerations
As with any medical treatment, safety is a crucial consideration. The clinical trial is carefully monitoring for any side effects or adverse reactions. Some general safety points to keep in mind:
- This medication is still being studied, so all potential side effects may not be known yet.
- It's given in combination with other cancer treatments, which may have their own side effects.
- The use of radioactive tracers involves exposure to small amounts of radiation, which doctors carefully control and monitor.
- Patients with certain health conditions or who are pregnant or breastfeeding may not be eligible to receive this treatment.
Remember, [89ZR]BMS-986279 is still in the research phase. If you have extensive-stage small cell lung cancer and are interested in this treatment, talk to your doctor about whether participating in a clinical trial might be right for you.